Clinical Trials in Sheffield, United Kingdom
2 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled210 locationsNCT06790693
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Breast CancerUrothelial CarcinomaSoft Tissue Sarcoma+2 more
Avacta Life Sciences Ltd158 enrolled9 locationsNCT04969835
Recruiting
Phase 1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Royal Marsden NHS Foundation Trust45 enrolled9 locationsNCT04360941
Recruiting
Not Applicable
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy
Breast CancerSentinel Lymph NodeNeoplasm, Breast
University Hospitals of Derby and Burton NHS Foundation Trust1,900 enrolled98 locationsNCT04109079
Recruiting
Phase 1Phase 2
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Breast Cancer
Novartis Pharmaceuticals58 enrolled32 locationsNCT06247995
Recruiting
Phase 1Phase 2
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Scancell Ltd168 enrolled16 locationsNCT05329532
Recruiting
Phase 2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Breast Neoplasm
Institute of Cancer Research, United Kingdom119 enrolled6 locationsNCT03740893
Recruiting
Phase 2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerER+ Breast Cancer
Royal Marsden NHS Foundation Trust1,100 enrolled49 locationsNCT04985266